9 results about "Erythrocyte lysis" patented technology

This invention belongs to the field of biomedical technology and provides a high-throughput drug screening system and its usage method for enriching circulating tumor cells (CTCs) in liver cancer. It includes an information processing and control unit; a diseased liver perfusion device comprising an organ chamber containing injection fluid at the bottom, an arterial supply line, an arterial end sensor, an arterial end clamp valve, at least two membrane lungs, a portal vein supply line, a portal vein end clamp valve, and a portal vein end sensor; a CTC enrichment device, which uses erythrocyte lysis to remove erythrocytes and immunomagnetic bead labeling to remove leukocytes, enabling the processing of large volumes of perfusion fluid in a single step to obtain enriched circulating tumor cells; a high-throughput drug screen; and phototubes, arterial end sensors, and portal vein end sensors, each electrically connected to the information processing and control unit. Compared with existing technologies, the high-throughput drug screening system and its usage method of this invention have the advantages of establishing a room-temperature mechanically perfused ex vivo liver cancer model, realizing the processing of large volumes of liquid specimens, and providing automated high-throughput drug screening functionality.

The present invention discloses a reagent composition for identifying mouse fibroblast subpopulations and a method for using the same, relating to the field of cell technology. The reagent composition includes an antigen blocking solution, an allophycocyanin (APC)-labeled Ly6C antibody, a phycoerythrin (PE)-labeled CyclinD1 antibody, a fluorescein isothiocyanate (FITC)-labeled DCN antibody, a PBS phosphate buffer, a cell digestion solution, and an erythrocyte lysis solution. The present invention can identify and sort DCN-positive fibroblast subpopulations in the lung tissue of mice with acute lung injury, or identify and sort DCN-positive fibroblast subpopulations in the lung tissue of mice with acute lung injury that are undergoing tissue damage or repair, providing conditions for in-depth research on the role and mechanism of DCN-positive fibroblasts in ARDS, and exploring clinical treatment or prognostic targets.

The invention provides a whole blood treatment agent, a kit and application of the whole blood treatment agent in detection of calprotectin, and relates to the technical field of in-vitro detection, the whole blood treatment agent comprises 5-15 mmoL / ml of ammonium chloride or 0.01-0.05 mg / ml of ascorbic acid oxidase, and a solvent is an enzyme diluent. The enzyme diluent is used as a solvent, so that the whole blood treatment agent maintains a stable environment in a sample treatment process, and related enzyme activity is maintained. Ammonium chloride promotes erythrocyte lysis to release hemoglobin; ascorbic acid oxidase can catalyze ascorbic acid to be oxidized into dehydroascorbic acid, and interference factors are reduced. By using the whole blood treatment agent, a tedious pretreatment step on a whole blood sample by using a sample treatment liquid is not needed, the directly collected whole blood sample can be used for subsequent detection after being mixed with the whole blood treatment agent, and the directly collected whole blood sample can be used for subsequent detection, so that the sample treatment is simplified, and the risk of introducing an error due to the sample treatment is reduced; a detection result accords with a clinical diagnosis result, and the accuracy is high.

To provide an antibody against CD38, a preparation method therefor and the use thereof.SOLUTION: The present disclosure relates to an antibody that binds to the CD38 protein or an antigen-binding portion thereof, a preparation method therefor and the use thereof. The antibody can bind to human CD38 with high affinity, has an inhibitory effect on the CD38 enzyme, has a CDC, ADCC, and / or ADCP killing activity with regard to different tumor cells, and has an anti-tumor function. Moreover, the antibody does not cause red blood cell lysis.SELECTED DRAWING: Figure 4-1

The application discloses a method for detecting circulating tumor cells based on cell membrane surface sialic acid expression quantity and single cell detection technology, and belongs to the field of biomedical technology. The method comprises the following steps: using a boron acid group modified probe to label cell surface sialic acid in a blood sample after erythrocyte lysis; passing the labeled sample through a phase transfer flow focusing chip to enrich and purify circulating tumor cells based on cell size; and detecting the enriched and purified cells by a single cell analysis method. The application solves the problems of high cost, long time consumption and high missed detection rate of the current circulating tumor cell detection method applied in clinical practice, and provides a method with simple operation and higher universality for circulating tumor cell detection.

The invention relates to the technical field of cell engineering, in particular to a placenta macrophage purification and culture method. Comprising the following steps: (1) cutting placenta tissues into pieces, adding an enzymatic hydrolysate for digestion, adding a red blood cell lysis buffer for ice bath, and adding a basic culture medium for resuspending cells to obtain a resuspended cell mixed solution; (2) adding the resuspended cell mixed solution to the upper layer of the lymphocyte separation solution, centrifuging, and sucking out macrophages to obtain purified macrophages; and (3) inoculating the purified macrophages into an amplification culture medium, and culturing to obtain the macrophages subjected to amplification culture. The invention provides an efficient and stable placenta macrophage purification and culture method, through optimized enzymolysis separation, gradient centrifugal purification and a specific amplification culture medium formula, the purity, the multiplication capacity and the functional stability of the macrophage are remarkably improved, and the placenta macrophage purification and culture method has a practical application value.

This invention belongs to the fields of biotechnology and precision oncology, and discloses a serum-free amplification method for circulating tumor cells (CTCs) based on apoptosis selectivity, along with a dedicated culture medium. This addresses the problems of existing CTC technologies, which rely on physical capture leading to impaired cell viability and low culture success rates. The invention involves mild density gradient centrifugation and erythrocyte lysis of anticoagulated whole blood from patients to obtain a mixed population of leukocytes containing CTCs. This population is then seeded into a serum-free, selective apoptosis medium for three-dimensional culture. The medium contains apoptosis inhibitors and specific growth factors. Utilizing the difference between tumor cells' anti-apoptosis and normal blood cells' susceptibility to apoptosis, leukocyte apoptosis is induced within 4-7 days, while simultaneously supporting CTC survival, adhesion, and clonal proliferation, enabling the amplification of individual CTCs into cell clusters. This method preserves the original activity and heterogeneity of CTCs, is simple to operate, and has good reproducibility, providing a highly active cell source for CTC molecular identification, drug sensitivity testing, and metastasis mechanism research.

The utility model discloses a blood pretreatment experiment tube which comprises a tube body, the internal pressure of the tube body is smaller than the external pressure, and a blood pretreatment reagent is arranged in the tube body. According to the utility model, a blood pretreatment reagent is placed in the blood collection tube, so that the sample treatment flow of red blood cells needing to be lysed is greatly shortened, and the experiment efficiency is improved. A traditional blood pretreatment method needs a plurality of steps and tools, while the blood collection tube can be used for directly carrying out erythrocyte lysis after blood collection, and additional operation is not needed. And secondly, the blood collection tube saves consumables and reduces the experiment cost. And an additional centrifugal tube or lysis solution container is not needed, so that the material consumption in the experiment process is reduced. In addition, according to the blood collection tube, the pollution risk in operation is reduced, and the accuracy and reliability of experiments are improved. The blood and the lysate are mixed and lysed in a closed environment, so that the interference of external pollutants is avoided, and the accuracy of an experimental result is ensured.

This invention belongs to the field of biomedical technology, specifically relating to a method and kit for improving the sensitivity and specificity of circulating tumor cell (CTC) detection. The method first treats anticoagulated blood with erythrocyte lysis buffer, centrifuges to obtain a cell suspension (including leukocytes and circulating tumor cells); then, a radiosensitizer is added and the suspension is irradiated; next, single-cell gel electrophoresis is used to detect the degree of DNA damage in the test cells; finally, leukocytes and tumor cells are distinguished based on cell morphology using a fluorescence microscope or fluorescence scanner. This invention is the first to detect the number and type of circulating tumor cells (CTCs) in peripheral blood based on ionizing radiation and radiosensitization effects, according to the degree of DNA damage in tumor cells. Compared with existing technologies, this detection method and kit are not only simple and rapid, but also significantly improve detection sensitivity and specificity. Furthermore, it is independent of the physical properties of cells and tumor cell surface markers, requires a small sample volume, is highly versatile, and can detect CTCs in different types of solid tumors.